Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells (original) (raw)
- Original Article
- Published: 06 July 2009
Post-transplant Events
- J El-Cheikh Jr2,
- F Hoffmann1,
- Y Hildebrandt1,
- F Ayuk1,
- C Wolschke1,
- D Atanackovic3,
- G Schilling3,
- A Badbaran1,
- U Bacher1,
- B Fehse1,
- A R Zander1,
- D Blaise2,
- M Mohty4 &
- …
- N Kröger1
Bone Marrow Transplantation volume 45, pages 349–353 (2010)Cite this article
- 1530 Accesses
- 88 Citations
- Metrics details
Abstract
We investigated efficacy and toxicity of lenalidomide in 24 heavily pretreated myeloma patients with a median age of 59 years (range: 37–70) and relapse after allo-SCT. Lenalidomide was given at a dose of 15 mg (_n_=4), or 25 mg (_n_=20), orally once daily on day 1 to day 1 every 28 days, with (_n_=20) or without (_n_=4) DHAP. The median number of lenalidomide cycles was five (range: 2–17). Major side effects were leukopenia (grade 4: 4%, grade 3: 21% and grade 2: 17%) and thrombocytopenia (grade 3: 17% and grade 2: 29%); infectious complications were observed in 50%. Non-hematological toxicity consisted of muscle cramps (_n_=9), fatigue (_n_=5) and constipation (_n_=2). Mild grade I–II GVHD was seen in three patients. Response was achieved in 66%: CR in 8%, VGPR in 8%, PR in 50% and SD in 13%. The median time to progression was 9.7 months (95% confidence interval (CI): 7.5–11.9), and median OS was 19.9 months (95% CI: 17.3–22.5). Immunomonitoring after lenalidomide showed significant increase of activated NK (NKp44+) and T (HLA-DR+) cells, as well as regulatory T cells (CD4+, CD25+, CD127lo), supporting an immunomodulating anti-myeloma effect of lenalidomide.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Figure 1
Similar content being viewed by others
References
- Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454.
Article CAS Google Scholar - Kröger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755–760.
Article Google Scholar - Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110–1120.
Article CAS Google Scholar - Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer HG et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004; 18: 659–662.
Article CAS Google Scholar - Kröger N, Krüger W, Renges H, Zabelina T, Stute N, Jung R et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001; 112: 421–423.
Article Google Scholar - Kröger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006; 34: 770–775.
Article Google Scholar - Kröger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104: 3361–3363.
Article Google Scholar - van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006; 107: 3415–3416.
Article CAS Google Scholar - Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005; 35: 165–169.
Article CAS Google Scholar - Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.
Article Google Scholar - Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142.
Article CAS Google Scholar - Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132.
Article CAS Google Scholar - Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM . Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4(+)Foxp3(+) T cells. Leukemia 2009; 23: 605–607.
Article CAS Google Scholar - Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005; 128: 192–203.
Article CAS Google Scholar - Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216.
Article CAS Google Scholar - Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 3940–3949. E-pub 2006 Jan 12.
Article CAS Google Scholar - Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291–1297.
Article CAS Google Scholar - Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 2008; 93: 423–430.
Article Google Scholar
Acknowledgements
We thank the staff of the BMT unit for providing excellent care of our patients, and the medical technicians for their excellent work in the laboratories. This work was supported in part by a grant from the Deutsche José Carreras Leukämie-Stiftung e.V. (to NK)
Author information
Authors and Affiliations
- Department for Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
M Lioznov, F Hoffmann, Y Hildebrandt, F Ayuk, C Wolschke, A Badbaran, U Bacher, B Fehse, A R Zander & N Kröger - Unité de Transplantation et de Thérapie Cellulaire (UTTC), Institut Paoli Calmettes, Marseille, France
J El-Cheikh Jr & D Blaise - Department for Oncology/Hematology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
D Atanackovic & G Schilling - CHU de Nantes, Hematologie Clinique, Universite de Nantes and INSERM, Nantes Cedex, France
M Mohty
Authors
- M Lioznov
You can also search for this author inPubMed Google Scholar - J El-Cheikh Jr
You can also search for this author inPubMed Google Scholar - F Hoffmann
You can also search for this author inPubMed Google Scholar - Y Hildebrandt
You can also search for this author inPubMed Google Scholar - F Ayuk
You can also search for this author inPubMed Google Scholar - C Wolschke
You can also search for this author inPubMed Google Scholar - D Atanackovic
You can also search for this author inPubMed Google Scholar - G Schilling
You can also search for this author inPubMed Google Scholar - A Badbaran
You can also search for this author inPubMed Google Scholar - U Bacher
You can also search for this author inPubMed Google Scholar - B Fehse
You can also search for this author inPubMed Google Scholar - A R Zander
You can also search for this author inPubMed Google Scholar - D Blaise
You can also search for this author inPubMed Google Scholar - M Mohty
You can also search for this author inPubMed Google Scholar - N Kröger
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toN Kröger.
Rights and permissions
About this article
Cite this article
Lioznov, M., El-Cheikh, J., Hoffmann, F. et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells.Bone Marrow Transplant 45, 349–353 (2010). https://doi.org/10.1038/bmt.2009.155
- Received: 20 February 2009
- Revised: 03 April 2009
- Accepted: 20 May 2009
- Published: 06 July 2009
- Issue Date: February 2010
- DOI: https://doi.org/10.1038/bmt.2009.155